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1. Introduction
Transplantation of autologous or allogeneic hematopoietic stem cells is a method currently
used to treat many malignant and nonmalignant hematological diseases. The indications,
methods, goals of therapy have evolved since the introduction of transplantation to the clini‐
cal practice. Progress that has been achieved allowed for the improvement of results. Thanks
to the availability of various conditioning regimens, various hematopoietic cells sources as
well as variable possibilities of anti-GvHD prophylaxis the individualization of the trans‐
plantation procedure has been more and more widely used in the recent years. This chapter
summarizes current clinical practices and presents major clinical problems that have to be
optimally managed in order to improve the outcomes of transplantation.
2. Autologous hematopoietic stem cells transplantation
Autologous peripheral hematopoietic stem cells transplantation (auto-HSCT) was for the
first time performed at Hammersmith Hospital in London in 1981 to treat the patient in ac‐
celerated phase of CML. Although auto-HSCT does not play any role in the treatment of
CML nowadays, indications for this valuable therapeutic method have evolved for many
years. In acute leukemia auto-HSCT should be recommended only in the context of clinical
studies. Auto-HSCT after myeloablative chemotherapy or radiotherapy has originally been
developed as an alternative to allogeneic hematopoietic stem cell transplantation for pa‐
tients with AML with no suitable donor. Several randomized studies in patients with AML
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in first complete remission (CR1) subsequently suggested reduced relapse rates after auto-
HSCT [1]. Auto-HSCT is also widely used to consolidate first remission in AML. The novel
molecular and cytogenetic stratification methods may allow the identification of AML enti‐
ties which could benefit from autografting. The overall survival of patients receiving auto-
HSCT in ALL in first remission is around 40%. The high-dose therapy followed by auto-
HSCT can be an alternative treatment in patients in whom allo-HSCT is precluded.
The results of a large European study showed that auto-HSCT can be recommended in pa‐
tients with good-risk cytogenetic characteristics of myelodysplastic syndrome [2]. Auto-
HSCT can be recommended as post-remission therapy to reduce the risk of relapse. The
longer remission was observed in patients who undergo auto-HSCT.
In myeloproliferative disorders auto-HSCT can induce responses in patients with primary
myelofibrosis, but this procedure cannot be recommended out of clinical protocols.
In chronic lymphocytic leukemia auto-HSCT can be considered for patients with poor-risk
disease in complete or good partial remission able to withstand high-dose therapy, but it
should be performed preferably in the context of clinical protocols.
Auto-HSCT is the standard therapy for patients with Hodgkin’s lymphoma (HL) in first che‐
mosensitive relapse or second complete remission as shown by two prospective randomized
clinical trials [3,4]. There is no indication for auto-HSCT in first remission, even in patients
with poor prognosis at diagnosis [5,6]. Patients refractory to first-line therapy but sensitive
to salvage therapy might benefit from auto-HSCT [7]. Auto-HCT might be considered as a
part of a clinical protocol for patients with resistant Hodgkin’s lymphoma, as an initial de‐
bulking therapy to be followed by an allo-HSCT as consolidation therapy [8].
In many non-Hodgkin’s lymphomas auto-HSCT is a standard therapy. In diffuse large B-cell
lymphoma (DLBCL) auto-HSCT is a standard therapy for patients with chemosensitive re‐
lapse [9]. The role of auto-HSCT is being re-evaluated with the advance of monoclonal anti‐
bodies and use of chemo-immunotherapy as first-line treatment. Auto-HSCT remains also
the standard approach for early relapsing patients with follicular lymphoma (FL) [10]. In
both DLBCL and FL, auto-HSCT does not provide any clinical benefit in patients with re‐
fractory disease. Otherwise, most patients with mantle cell lymphoma are being offered an
early intensification with an auto-HSCT, owing it to the inherent poor prognosis of the dis‐
ease. The retrospective analysis indicates that the results of auto-HSCT performed beyond
the first remission are inferior [11]. Few studies showed an improved survival in patients
with T-cell non-Hodgkin’s lymphoma (NHL) who received auto-HSCT as a first line treat‐
ment, compared to those who did not.
Patients with multiple myeloma form a large group of patients being transplanted. Auto-
HSCT is clearly indicated for patients <70 years of age with satisfactory general health and
fitness who respond to the first-line treatment. Although new agents change the place of au‐
to-HSCT in MM, this procedure still has an established position in treatment. Best results are
observed in patients achieving good response before the auto-HSCT, but some non-respond‐
ing patients also may benefit from this approach. Double auto-HSCT (or tandem auto-
HSCT) has been shown to be superior to consolidation and maintenance with agents such as
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thalidomide in patients not achieving the remission or a very good partial response after the
first transplant [12].
Auto-HSCT constitutes an important treatment option for patients with solid tumors. Select‐
ed subgroups of oncological patients may benefit from high-dose chemotherapy supported
by auto-HSCT. High-dose chemotherapy for refractory germ cell tumors is considered a
standard therapy. Conditioning regimen in this case incorporates carboplatin and etoposide.
Auto-HSCT after conditioning regimen aimed to increase the immunosuppression is being
considered in clinical protocols for selected patients with severe multiple sclerosis [13],
rheumatoid arthritis [14], systemic lupus erythromatous [15], systemic sclerosis [16], im‐
mune cytopenias and Crohn’s disease [17]. Auto-HSCT for other autoimmune disorders is
being considered on a developmental basis. Steroid dependency with Cushing threshold
and skeletal damage could be an indication.
3. Allogeneic hematopoietic stem cell transplantation
Allogeneic hematopoietic stem cell transplantation (allo-HSCT) constitutes a standard treat‐
ment of hematological malignant and nonmalignant disorders. The possibility of finding a
donor has been increased by use of unrelated donors, with similar results of transplantation
when compared to results of sibling donor transplants. The use of peripheral blood stem
cells, instead of bone marrow, results in faster engraftment, but also in the increased risk of
chronic GvHD (Graft versus Host Disease). Reduced-intensity conditioning is used instead
of high–dose myeloablative conditioning for older patients and those with comorbidities.
Disease relapse is a major problem and thus it should be detected as early as possible, at the
stage of the minimal residual disease or recurrent recipient chimerism and managed by im‐
munotherapy with donor lymphocyte infusions. Novel diagnostic tools and anti-microbial
drugs have reduced the morbidity and mortality from infections.
Allogeneic hematopoietic stem cell transplantation connected with application of high-dose
chemo- and radiotherapy was first carried out by Thomas et al. in 1957 to treat leukemia pa‐
tient in advanced stage [18]. The concept of treatment at that time was based on the previous
observations conducted during the second world war, referring to destructive activity of ra‐
diation on the function of bone marrow, as well as further research conducted in the 1950’s,
which showed that it was possible to avoid irreversible pancytopenia thanks to the bone
marrow cells transplantation in the irradiated animals. The discovery of Human Leucocyte
Antigen (HLA) enabled to match appropriately the donor and the recipient, what contribut‐
ed to the significant increase in overall survival after transplantation which has been ob‐
served since 1968 [19]. The improvement of the results was undoubtedly also influenced by
other factors: performing the transplantation in the optimal phase- remission of the disease,
GvHD prevention, the improvement of adjunctive treatment. Nowadays more that 25.000
allo-HSCTs are being performed each year.
The main indication for allo-HSCT is acute myeloblastic leukemia (AML) and acute lympho‐
blastic leukemia (ALL). In high risk ALL and AML, when favorable prognostic genetic
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changes are lacking, the allo-HSCT is recommended in the first remission of the disease. The
transplantation in more advanced stages of the disease leads to the higher relapse rate, as
well as to the increased incidence of transplantation complications.
Despite the introduction of tyrosine kinase inhibitors (TKIs) into the treatment of chronic
myeloid leukemia (CML) over ten years ago, allo-HSCT still remains the only way of treat‐
ment capable to provide the complete recovery. The standard indication for allo-HSCT is re‐
sistance to TKIs treatment, especially in young patients. Other indications for allo-HSCT are
myelodysplastic syndrome, high-risk chronic lymphocytic leukemia, selected patients with
high-risk lymphoma, patients with myelofibrosis and other myeloproliferative neoplasms of
unfavorable prognosis. The results of multiple myeloma treatment with the use alloHSCT
are encouraging. AlloHSCT with the reduced conditioning regimen after previous auto-
HSCT constitutes an interesting alternative in patients with multiple myeloma patients, who
undergo single or tandem autologous transplantation [20].
Allo-HSCT is also the standard treatment in nonmalignant diseases of hematopoietic system
such as severe aplastic anemia (SAA), paroxysmal nocturnal hemoglobinuria (PNH) and he‐
moglobinopathies. In some cases of inborn metabolic defects, allogeneic transplantation of
donor’s cells can restore the production of the deficient or lacking enzyme and eliminate the
disease [21].
4. Hematopoietic stem cell donors
The optimal donors are siblings possessing both haplotypes identical with the recipient. The
syngeneic transplantation, i.e. from monozygotic twins, is the safest from the immunological
point of view, however it is connected with the increased risk of the relapse of the disease
resulting from the lack of immunological interaction between the donor cells and the recipi‐
ent cells [22].
Probability of possessing matched sibling donor is defined by the formula: 1–(0.75)n, were n
indicates the number of siblings. The observed decrease in the number of newly born chil‐
dren causes problems in finding matched family donors for many patients. In rare cases
with no matched sibling donor, matching donor could be found among other members of
the family. In the vast majority of patients without matched sibling donor, transplantation
from unrelated donor is the most frequently chosen option. The number of such transplanta‐
tions has increased considerably in the last 20 years [23]. It has been made possible thanks to
dynamic development of bone marrow donors’ registries, whose number of potential do‐
nors exceeded 20 million in the current year 2012. Alternatively, for those patients who are
unlikely to find a matched donor, partial incompatibility could be accepted.
The most desirable model of the donors’ registry organization is the development of nation‐
al ones which, for many reasons (safety of donors, clearness of procedures and financial rea‐
sons), according to WMDA’s (World Marrow Donors Association) recommendations should
control and supervise the recruitment of the donors within the country. The chance to find
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the matched donor depends on the frequency of occurrence of HLA-haplotypes in the whole
population and the race of recipient – most donors recruited by registries worldwide belong
to Caucasian race. The efforts are being made, especially in the USA, aiming to recruit high‐
er number of donors of other races.
Phenotypic HLA-matching involving the testing of HLA-antigens by means of specific sera
has been replaced by more precise molecular testing enabling the precise identification of
HLA allelic determinants.
The question of accepting a mismatched donor for a patients, who didn’t find a fully match‐
ed donor has not been finally solved. With the increasing number of observations there are
recommendations concerning optimal matching not only in HLA-A, B and DR, but also in C,
DQ and even DP. Many centers aim to transplant patients only from donors fully matched
in 10/10 alleles of HLA-A, B, C, DR and DQ. The improved methods of typing enabling
more precise molecular donor matching has improved the results of allo-HSCT from unre‐
lated donors, which are now similar to those of allo-HSCT from siblings [24]. As the allo-
HSCT from an unrelated donor has to be preceded by often time-consuming search for a
donor, it is important to plan the transplantation carefully in advance.
5. The sources of hematopoietic stem cells
The choice of the cells source depends of diagnosis and the type of conditioning treatment
applied. Collection of bone marrow is preferred in nonmalignant diseases in order to avoid
chronic GvHD. Transplantation of hematopoietic cells from peripheral blood is preferred
when reduced intensity conditioning regimen is used, with regard to the fact that transplan‐
tation of larger number of hematopoietic cells is able to break the resistance of the recipient
and to result in the engraftment.
The bone marrow aspirated in general anesthesia from iliac spine was for many years the
main source of cells for transplantation. Except of hematopoietic cells, the bone marrow also
consists of multipotential mesenchymal cells which, although are not hematopoietic cells,
have a potential to differentiate in vitro and in vivo into various mesenchymal tissues, such
as bone, cartilage, fat tissue, tendons and bone matrix. Mesenchymal stem cells can reduce
the alloreactivity, they inhibit lymphocytes T proliferation and act immunosuppressively,
what has been implemented in the form of unrelated or haploidentical mesenchymal cells
infusion into the treatment of acute GvHD.
During the 1990’s the cells collected in apheresis from peripheral blood after their previous
stimulation with granulocytic stimulating factor (G-CSF) completely superseded the bone
marrow aspiration in autologous transplantations. In the beginning of 21st century, the simi‐
lar trend occurred also in allo-HSCT. The apheresis of cells from peripheral blood usually
results in collection of higher number of nucleated cells, CD34+ cells, lymphocytes CD3+
and NK cells when compared with cells aspiration from the bone marrow; it enables faster
regeneration of granulocytes and platelets. It translates into the smaller risk of infections and
smaller demand for transfusions of blood derivatives.
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In the beginning allo-HSCT in the form of PBSCT (Peripheral Blood Stem Cells Transplanta‐
tion) was applied only in sibling transplantations due to the anxiety of acute GvHD occur‐
rence, however, the frequency of GvHD is similar to the one after bone marrow
transplantation, despite greater number of T-lymphocytes in the transplantation material
collected from peripheral blood, as it was shown in the number of studies. Thus allo-PBSCT
has been successfully applied also in allo-HSCT from unrelated donors. However, the fre‐
quency of chronic GvHD is higher, and thus allo-PBSCT is applied seldom in patients with
nonmalignant disease, who do not benefit from Graft versus Leukemia (GvL) effect, which
is usually connected with chronic GvHD [25].
The important source of hematopoietic stem cells for allo-HSCT is a cord blood (CB), usually
intended to be discarded. In many countries there are banks of frozen CB units where there
are over 0,5 million units ready to be transplanted. The advantage of applying CB cells is
their immediate availability and a reduced risk of GvHD, related to a relative shortage of
mature T-lymphocytes in the CB. Therefore the higher level of HLA-mismatching between
the donor and the the recipient is more acceptable in CB transplantation than in traditional
transplantations. The unfavorable factors are a more frequent occurrence of graft failure and
a slower regeneration responsible for higher risk of infections. The number of necessary
nucleated cells and CD34+ cells calculated per kilogram of the recipient’s body mass is lower
by about one logarithm when compared to the bone marrow. A number of studies showed
the importance of sufficient number of cord blood nucleated cells, for this reason it is recom‐
mended to transplant more than 2x10^7 nucleated cells per kilogram of recipient’s body
mass. It constitutes limitation in CB application in adults due to the small volume of cord
blood and small total number of cells. Simultaneous transplantation of two CB units is suc‐
cessfully applied to solve this problem [26,27]. In vitro cells expansion to increase the num‐
ber of CB cells has not been widely used. Because of the limited, usually small number of
cord blood cells, it is most often applied as the source of cells for transplantation in children.
6. Preparative treatment before transplantation
The preparative treatment before transplantation (or conditioning regimen) aims to eradi‐
cate the remains of the disease and to make immunological system of recipient weaker in
order to enable the acceptance of the graft by the recipient. The preparative treatment is con‐
nected with toxicities which turned out to be impossible to eliminate so far.
The choice of conditioning treatment depends of the patient’s age, the main disease and co‐
existing diseases. Myeloablative conditioning regimens are characterized by strong cytotox‐
icity as well as strong immunosuppressive potential, while reduced intensity conditioning
regimens differ in cytotoxic activity and immunosuppressive potential. They are chosen de‐
pending on the main disease and evaluation of the risk of graft failure.
The combination of radiotherapy (TBI- total body irradiation- at total dose of 12 Gy, deliv‐
ered in fractions) and cyclophosphamide (Cy, at total dose of 120 mg/kg administered with‐
in 2 days) has been used for over 40 years for conditioning [28]. TBI treatment is
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recommended as a standard in ALL. In order to avoid potential TBI consequences, such as
bronchiolitis obliterans, cataract, secondary malignancy, endocrinological disorders, inhibi‐
tion of the growing process in children, TBI in AML and MDS has been replaced by busul‐
fan given at 16 mg/kg dose within 4 consecutive days before Cy [29]. The BuCy treatment
has higher risk of SOS (sinusoidal obstruction syndrome), hemorrhagic cystitis and chronic
GvHD. The high serum concentration of Bu (Busulfan) occurring during its oral treatment
has influenced considerably its toxic complications. It is difficult to avoid it because of vari‐
ous degree of absorption from digestive tract. Thus the intravenous use of busulfan is more
favorable. The reduction of SOS incidence and decrease of transplant related mortality
(TRM) after intravenous use of Bu has been reported [30]. In order to further limit the toxici‐
ty, treosulfan is used instead of Bu in modern treatment programs nowadays, and addition‐
al immunosuppressive effect is obtained by parallel application of purine analoque, e.g.
fludarabine.
The standard preparative treatment applied in SAA comprises of Cy 200 mg/kg and antithy‐
mocyte globulin (ATG).
Although the intensive conditioning treatment decreases the risk of relapse after transplan‐
tation, it does not prolong the overall survival because greater toxicity leads to increased
transplant related mortality [31].
The concept of so-called RIC (reduced intensity conditioning) incorporates the advantage of
anti-leukemic effect of donor T-lymphocytes while cytotoxic effect of conditioning regimen
is decreased. The main result of RIC treatment is immunosuppressive therapy aiming to en‐
able the acceptance of the transplant by braking the immunological defence of the recipient.
The anti-leukemic effect can be escalated after transplantation by means of DLI (Donor Lym‐
phocyte Infusion), whenever it is required. DLI was first used with success in CML patients,
in whom the disease relapsed after conventional allo-HSCT [32]. Since then it has been used
in many other diseases, including many clonal diseases of hematopoietic system, most often
lymphomas and chronic lymphocytic leukemia (CLL). RIC treatment has lower toxicity
when compared to conventional conditioning treatment, thus it is suitable for transplanta‐
tion in older patients and in patients with coexisting diseases in whom the application of
myeloablative treatment is contraindicated. RIC treatment consists most often of purine ana‐
loque. The example of RIC treatment reduced to the minimum, after which graft occurs, is
the combination of TBI dose 2Gy with fludarabine. Other exemplary RIC protocols are the
combination of fludarabine with Bu at dose 8 mg/kg and ATG with Cy or with melphalan.
The important element of RIC treatment is the use of immunosuppressive therapy after
transplantation e.g. cyclosporine A and mycophenolate mofetil. The reduced intensity of
conditioning enables the immunocompetent recipient cells to survive until the moment of
transplantation, what leads to the higher risk of graft failure or incomplete graft. In some
centers transplantation with RIC are performed in ambulatory, however patients often re‐
quire further hospitalization due to infections or GvHD [33].
Allo-HSCT with use of RIC can be applied when autologous transplantation is ineffective.
Other possibility is to apply the tandem transplantation: at first autologous one and then the
allogeneic one, with use of RIC in order to reduce the TRM by separation of high-dosed cy‐
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totoxic treatment from immunotherapy related to allogeneic HSCT, which has been applied
for the first time in patients with multiple myeloma (MM).
7. Adjunctive treatment
During the phase of pancytopenia after myeloablative conditioning patients are usually sus‐
ceptible to infections and thus they have to stay in a sterile environment, e.g. in HEPA-fil‐
tered rooms with reversed isolation. They routinely receive preventive treatment against
bacteria, viruses, fungi. Moreover, the substitution treatment is applied with the use of irra‐
diated, CMV-negative red blood cells and single donor platelets concentrates. Analgetic
drugs and parenteral nutrition are applied when needed. Ursodeoxycholic acid is used in
order to avoid hepatic complications. G-CSF is applied to accelerate the regeneration of
granulocytes, however it can delay the recovery of platelets and can increase the risk of
GvHD. Erythropoietin accelerates the recovery of red blood cells system and thus it reduces
the need for transfusions, but it increases the cost of the transplant procedure and it is not
used on a regular basis.
8. Post-transplant complications
8.1. Graft versus host disease
Acute and chronic graft versus host disease are the main complications of allo-HSCT. In
pathophysiology of acute and chronic GvHD, T-lymphocytes of the donor recognize HLA-
molecules of the recipient presented by the antigen presenting cells. It results in the release
of interleukin-2 and activation of cytotoxic T-lymphocytes, NK-cells and macrophages. The
main targets of the attack are skin, gut and liver. The most important risk factor is the HLA-
incompatibility between the donor and the recipient, but also minor histocompatibility anti‐
gens are responsible for the risk of GvHD, especially HY mismatch in case when the donor
is female and the recipient is male [34]. Chronic GvHD occurs most often from 100 days to
one year after allo-HSCT. It resembles autoimmunological diseases, e.g. systemic scleroder‐
mia and Sjoegren syndrome. Symptoms such as lichen and sclerodermic skin changes, mu‐
cositis, kserostomia, keratoconjunctivitis sicca, stricture of esophagus and vagina, cholestatic
liver failure, bronchiolitis obliterans and musculitis also occur. Cachexia, immunological de‐
ficiency, additionally increasing the risk of infections especially caused by gram-plus bacte‐
ria can be also observed. The initial stage of chronic GvHD is usually more progressive
when it is preceded by the acute form of the disease. It can also occurr after nonsymptomatic
(quiescent) period or de-novo, without any preceding symptoms of acute GvHD. The chron‐
ic progressive GvHD has the worst prognosis.
In order to decrease the risk of GvHD a preventive immunosuppression, usually with the
use of cyclosporine A (CsA) and methotrexate is applied. The removal of T-lymphocytes
from the transplanted cells (T-depletion) constitutes the effective form of prevention, how‐
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ever, it is connected with the higher risk of the graft failure and relapse of the disease. In
cord blood transplantations, instead of methotrexate which prolonges the regeneration peri‐
od, prednisolon is used. New immunosuppressive protocols include calcineurin-inhibitors
other than cyclosporine A – tacrolimus, macrolid immunosuppressant– syrolimus and my‐
cophenolan mofetil. The administration of ATG before transplantation is an important im‐
munosuppressive element used in allo-HSCT from unrelated donors. As the effective serum
concentration of ATG is maintained for many weeks after infusion, it effects not only T-lym‐
phocytes of the recipient but also those of the donor [35]. The increased risk of infections is
an undesirable side effect of ATG.
The type of GvHD prevention depends of the diagnosis, the type of conditioning treatment
and the applied cell source. The GvHD prevention should be more effective in nonmalig‐
nant disease and less intensive when lower number of cells have been transplanted.
When symptoms of acute GvHD develop despite its prophylaxis, methylprednisolone at the
dose of 2-5 mg per kilogram of body weight per day is used on the standard basis, usually
effectively. In case of steroid resistance the risk of failure is high. The second line treatment
consists of ATG, anti-IL-2 antibodies, anti-IL-2 receptor antibodies and antibodies against
TNF-alpha. Photosensitizing psolarens and ultraviolet radiation in a form of extracorporal
photopheresis and transplantation of mesenchymal stem cells can be also applied, but are
not everywhere available. Mesenchymal stem cells have strong immunosuppressive effect,
they can be obtained from the primitive connective tissue of the umbilical cord, called the
Wharton’s jelly, and they do not require any matching due to low levels of HLA-ABC and
lack of HLA-DR antigens.
The treatment of chronic GvHD consists of CsA and steroids. In patients not responding to
the treatment tacrolimus, thalidomide, mycophenolan mofetil, sirolimus and irradiation of
lymphatic system with dose of 1 Gy can be applied.
8.2. Infections
Immunological  reconstitution  is  of  a  primary  importance  to  avoid  infections  after  allo-
HSCT. The highest risk of the infection occurs in patients with GvHD, but also in the re‐
maining patients with no GvHD it is 20 times higher than in the whole population. From
20% up to 50% of patients still require immunosuppressive treatment after 3 years from al‐
lo-HSCT, what considerably increases the risk of infectious complications in this group of
patients [36].
Normal endogenous Gram-negative flora from the gastrointestinal tract and exogenous
catheter-related Gram-positive bacteria constitute the most frequent cause of infections in
the early stage after allo-HSCT. In this stage fungal infections are also the problem, especial‐
ly other than Candida albicans, which are usually recognized with the delay. Although my‐
cological diagnosis based on PCR method is available, it has not been introduced into
practice yet. Galactomannan testing and detection of specific fungal antigens in the blood
are sometimes helpful. In the treatment we already administer not only conventional am‐
photericine B with considerable side effects, but also its lipid-based preparations (Abelcet,
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AmBisome, Amphocil) being better tolerated, but unfortunately expensive. New antifungal
drugs such as echinocandins (caspofungin, anidulafungin, micafungin) and newer azole
drugs (voriconazole, posaconazole) are also currently available.
After  resolution  of  pancytopenia  cytomegalovirus  infection  is  a  most  frequent  problem.
Thanks  to  a  modern  diagnostic  approach  based  on  early  CMV  antigen  detection  by
means of  PCR methods,  CMV reactivation can be  detected and cured before  CMV dis‐
ease is developed. The most common cause of CMV infection is latent virus reactivation
in  CMV-seropositive  patient  or  CMV-transmission  from a  seropositive  donor  to  a  sero‐
negative  recipient.  Therefore  the  optimal  situation  is  when the  serological  status  of  the
donor and the recipient is identical. The antiviral prevention includes the substitution of
blood  products  from  CMV-seronegative  donors,  transfusion  of  immunoglobulines  and
administration  of  antiviral  drugs  such  as  gancyclovir,  foscavir,  cydofovir  and  oral  val‐
gancyclovir.  Polyoma- BK virus and adenovirus are common causes of  dysuria,  urinary
tract  infections and haemorrhagic  cystitis  in immunocompromised patients.  Epstein-Barr
virus can cause post-transplant  lymphoproliferative disease (PTLD).  The risk factors  are
the use of  anti-thymocyte globulin and transplantation from unrelated donors.  Monitor‐
ing of  EBV-viremia by means of  PCR methods enables  to start  the treatment early –  to
reduce  the  immunosuppression  and  to  use  rituximab  (anti-CD20  antibody)  and  donor
lymphocyte infusion (DLI).
8.3. Relapse of the disease
Having better adjunctive treatment and more effective GvHD prevention, the relapse of ba‐
sic disease constitutes the main cause of allo-HSCT failure. The risk of the relapse depends
on the type of the disease, its stage at the moment of transplantation and the GvHD preven‐
tion applied (the more effective immunosuppression, the higher risk of the relapse). The lon‐
gest survival time is observed in patients with moderate acute or limited chronic GvHD,
because of the lowest risk of the relapse.
Although the relapse after allo-HSCT can be treated by means by DLI, good prognosis refers
usually to the patients with CML. In acute leukemia relapsing after allo-HSCT the tempora‐
ry response can be also achieved, but it is usually not stable.
Patients with molecular CML relapse, i.e. with reappearance of bcr/abl transcript in PCR
tests, have better prognosis than those with hematological relapse. The prognosis in patients
with more advanced stages of CML- relapse, acceleration phase or blastic transformation- is
much worse. The relapse should by detected as soon as possible, when there is still a chance
for effective immunotherapy after allo-HSCT.
The alternative to specific disease markers determination is post-transplant chimerism test‐
ing. The PCR short tandem repeats (STR) method is used. The goal of allo-HSCT is to obtain
the full donor’s chimerism. Detection of returning or increasing recipient’s chimerism can be
a sign of the relapse of the disease, similarly to the re-occurrence of minimal residual disease
[37]. In such case it is recommended to use adoptive immunotherapy by reduction of immu‐
nosuppressive treatment and DLI application. The chimerism testing is important also for
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prediction and analysis of the graft failure and GvHD risks. GvHD and pancytopenia can
develop as the side effects of DLI. The use of T-lymphocytes in escalating doses is equally
effective as high DLI dose, but it decreases the risk of GvHD [38].
9. New indications for transplantation of hematopoietic stem cells
Allo-HSCT with subsequent immunotherapy can be applied in patients with metastatic sol‐
id tumors. The presence of graft versus tumor effect has been shown in kidney cancer, colon
adenoma, metastatic breast, ovarian, prostate and pancreas cancers. RIC treatment has been
used in these conditions in order to reduce TRM while enabling to achieve the response,
which was complete in some cases [39]. The presence of fewer than 3 metastases and Kar‐
nofsky scale ≥70 constitutes beneficial prognostic factors [40]. The survival is longer in pa‐
tients who develop chronic GvHD after DLI.
Allo-HSCT is currently tested in animal models and in experimental clinical applications.
Hematopoietic stem cells are characterized by plasticity, which means that they can form
not only blood cells. Hematopoietic stem cells can be forced to transform into the cells of
various tissues such as heart muscle, bone or blood vessels in suitable conditions [41]. The
science dealing with plasticity of stem cells is just developing, but it arises hope for revolu‐
tion in the way of thinking about transplantation and organ regeneration.
10. Conclusion
Allo-HSCT procedure has transformed from the experimental method of treatment of leuke‐
mia in its final stage into routine procedure applied in patients with various hematological
diseases. The ability to collect and to transplant hematopoietic cells makes it possible to cure
many patients with malignant and nonmalignant diseases incurable with other methods.
Thanks to development of unrelated donor registries the treatment with allo-HSCT can be
currently offered not only to the patients having HLA-matched sibling donor but to almost
every patient in need. The observed increase of transplantations of peripheral hematopoietic
stem cells results from observed faster regeneration of hematopoietic system than after bone
marrow transplantation and from beneficial GvL effect in clonal diseases, although it coin‐
cides with more frequent occurrence of GvHD.
The patients in the older age group and those with comorbidities can be treated with allo-
HSCT after preparation with RIC. Still, the main problem is the relapse of the disease, how‐
ever when it is detected early basing on chimerism analysis and minimal residual disease
evaluation, it can be successfully treated with immunological intervention with DLI. Recent
and current studies indicate that hematopoietic stem cells will be used for new clinical appli‐
cations in the near future.
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